Company Profile
Outlook Stock Price, News & Analysis
- Ticker:
- OTLK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.97 USD (-5.58%)
Close
Last updated: August 6, 2026
121M USD
Market cap
Why the stock is moving
Following the latest company update, “Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026”, OTLK closed down 5.58% at $0.9725 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Business overview
Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Outlook sits in specialty biotechnology.
Business Model Characteristics
The business depends on regulatory milestones, product launch execution, and the commercial opportunity in retina care.
Position Within the Biotechnology Landscape
Outlook is a catalyst-sensitive ophthalmology name with high sensitivity to approval and launch outcomes.
Future catalysts
Outlook's catalyst setup now looks most tied to ONS-5010 and bevacizumab. What gives this more shape is Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010. That setup makes the next update more important than the headline financials themselves.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Outlook (OTLK)?
Outlook (OTLK) most recently closed at 0.97 USD, a -5.58% move versus the previous session.
What is the market cap of Outlook (OTLK)?
Outlook currently has a market capitalization of 121M USD on BioPharmSignal.
What does Outlook do?
Outlook Therapeutics is an ophthalmology company focused on retinal disease and anti-VEGF therapy delivery. Its story centers on whether it can create a differentiated eye-care franchise.
On which exchange is OTLK stock listed?
Outlook (OTLK) is associated with NASDAQ, United States, Biopharma.
What is ONS-5010?
Outlook's catalyst setup now looks most tied to ONS-5010 and bevacizumab.
Which conditions is Outlook targeting with ONS-5010?
Outlook is associated with ophthalmology based on its company overview and current catalyst commentary.
How does Outlook describe recent progress with ONS-5010?
Outlook's catalyst setup now looks most tied to ONS-5010 and bevacizumab.
What is bevacizumab?
Outlook's catalyst setup now looks most tied to ONS-5010 and bevacizumab.